Publications by authors named "Alicia Ali"
Article Synopsis
- The study looked at how often men with advanced prostate cancer get tested with a special method called next-generation sequencing (NGS) to find helpful information about their disease.
- They analyzed data from 1,597 patients and found that only 9% had more than one NGS test, often discovering new useful information on the second test.
- The results suggest that doing these tests more than once could help doctors make better treatment choices for men with advanced prostate cancer.
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Prostate Cancer Prostatic Dis
February 2024
Article Synopsis
- The study investigates how alterations in the androgen receptor (AR) gene affect the treatment outcomes for patients with castration-resistant prostate cancer (CRPC) receiving androgen receptor-targeting agents (ARTA).
- Researchers analyzed data from the PROMISE database, looking at patients' genomic testing results in relation to their ARTA treatment timing and clinical outcomes.
- Findings indicate that AR amplifications correlate with a longer time to disease progression, highlighting the need for more in-depth studies to better understand these genomic alterations' impact on treatment responses.
Background: gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes remains unclear.
Methods: Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing and received ARTA treatment were identified in the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database.
Article Synopsis
- - This study analyzes the efficacy of enfortumab vedotin (EV) for treating advanced urothelial cancer (aUC) in patients not previously well represented in clinical trials, focusing on real-world experiences from a retrospective study called UNITE.
- - The results from 304 patients indicated a 52% overall response rate to EV monotherapy, with similar responses in various patient subsets, including those with significant comorbidities that were often excluded from clinical trials.
- - Overall survival was about 14.4 months, showing that EV can be effective even for patients with variant histology or specific genetic alterations, aligning with earlier clinical trial findings.
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Prostate Cancer Prostatic Dis
September 2022
Purpose: Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to enhance our characterization of advanced prostate cancer and further enable precision oncology.
View Article and Find Full Text PDFImmunotherapy induces durable clinical responses in a fraction of patients with cancer. However, therapeutic resistance poses a major challenge to current immunotherapies. Here, we identify that expression of tumor stanniocalcin 1 (STC1) correlates with immunotherapy efficacy and is negatively associated with patient survival across diverse cancer types.
View Article and Find Full Text PDFPurpose: Several immune checkpoint inhibitors (ICIs) are FDA approved for treatment of genitourinary (GU) malignancies. We aim to determine demographic and clinicopathologic characteristics that significantly affect clinical outcomes in patients with advanced stage GU malignancies treated with ICIs.
Materials And Methods: We performed a single-center, consecutive, retrospective cohort analysis on patients with metastatic or unresectable GU malignancies who were treated with ICIs at the University of Michigan.
Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience.
Cancer Treat Res Commun
November 2021
Introduction: Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognosis. We sought to compare outcomes between patients who received immunotherapy (IO) including CPIs or high dose interleukin-2 (HD IL2) for metastatic sRCC versus those who did not.
Patients And Methods: We performed a single-center retrospective data analysis of 44 consecutive sRCC patients with any percentage of sarcomatoid differentiation from our institutional RCC database of whom 34 received IO and 10 patients did not.
NMDA-type glutamate receptors mediate both trophic and excitotoxic signalling in CNS neurons. We have previously shown that blocking NMDAR- post-synaptic density-95 (PSD95) interactions provides significant protection from excitotoxicity and in vivo ischaemia; however, the mechanism of neuroprotection is unclear. Here, we report that blocking PSD-95 interactions with the Tat-NR2B9c peptide enhances a Ca²⁺-dependent protective pathway converging on cAMP Response Element binding protein (CREB) activation.
View Article and Find Full Text PDF